Genetic Studies on Chromosome 12 in Late-Onset Alzheimer Disease

William S. Wu, MS; Peter Holmans, PhD; Fabienne Wavrant-Devrieze; Shantia Shears; Patrick Kehoe; Richard Crook; Jeremy Booth; Nigel Williams; Jordi Pérez-Tur, PhD; Kimberly Roehl; Iain Fenton; Marie-Christine Chartier-Harlin, PhD; Simon Lovestone, MD; Julie Williams, PhD; Mike Hutton, PhD; John Hardy, PhD; Michael J. Owen, MD; Alison Goate, PhD

Context.—The only genetic locus universally accepted to be important as a risk factor for late-onset Alzheimer disease (AD) is the apolipoprotein E (APOE) locus on chromosome 19. However, this locus does not account for all the risk in late-onset disease, and a recent report has suggested a second locus on chromosome 12p11-12.

Objective.—To look for evidence of linkage on chromosome 12 and to test for the presence of the new locus in an independent sample of familial late-onset AD cases.

Design.—Retrospective cohort study. As part of a 20-centimorgan genome screen (approximately equal to 200 markers), we tested a series of 18 genetic markers on chromosome 12 and carried out multipoint, nonparametric lod score and exclusion analyses.

Setting.—Clinic populations in the continental United States selected from the National Institute of Mental Health AD Genetics Consortium.

Patients.—We selected samples for DNA analysis from affected sibling pairs, 497 subjects from 230 families with 2 or more affected individuals with probable or definite AD with onset ages older than 60 years (mean±SD, 75 ± 6 years). Within the families, we used the 2 probable or definitely affected individuals. In families with more than 2 such cases available, we used all of them; in families with only 2 such cases in which unaffected individuals were available, we also sampled the oldest unaffected individual and used genotype data from this unaffected individual to check for nonpaternity and genotyping errors.

Main Outcome Measure.—Presence of linkage or locus on chromosome 12.

Results.—Although linkage analyses confirmed the presence of a genetic susceptibility factor at the APOE locus in these families with late-onset AD, we were unable to confirm the presence of a locus close to the marker D12S1042. A moderate lod score (1.91) was found near D12S98 close to the α2-macroglobulin locus in the affected pairs in which both members did not possess an APOE ε4 allele.

Conclusions.—APoE remains the only locus established to be a risk factor for late-onset AD. We were unable to confirm that a locus on chromosome 12p11-12 has a major effect on risk for late-onset AD, although an effect smaller than that for APOE cannot be excluded.

LATE-ONSET Alzheimer disease (AD) shows familial clustering but does not show a clear mode of inheritance. The only genetic locus universally accepted as an important risk factor for late-onset AD is the apolipoprotein E (APOE) locus on chromosome 19. However, the APOE locus accounts for, at most, about half of the genetic risk of developing the disease. Thus, other genes or risk factors must account for the remaining genetic risk for developing disease.

See also pp 614 and 652.

Several strategies can be used to define these other genetic risk factors: (1) the analysis of large pedigrees with late-onset disease; however, few suitable pedigrees have been ascertained; (2) the genetic analysis of population isolates with disease; again, few such isolates have been reported; (3) the use of association studies between alleles of candidate genes and disease; and (4) the application of genome search strategies using large numbers of sibling pairs.

Association studies have the advantage of simplicity and speed since all that is required is the availability of a case-control series of DNA samples that can be tested for the presence of particular alleles. Furthermore, association studies can detect relatively small increases in risk associated with particular alleles. However, since the identification of the APOE locus, a large number of positive-association studies have been reported for AD, but none of these have been consistently confirmed. These failures to confirm associations may reflect different etiologies in different populations, type 1 statistical errors (a particular problem because multiple testing is always involved), or linkage disequilibrium between the tested polymorphism and the functional polymorphism (with this disequilibrium not present in all populations). In addition, association studies are sensitive to population substructure and unnoticed ethnic differences, which may affect the response to association.
Table 1.—Family Structure Comparison

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>This Series</th>
<th>Duke Series</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of Families</td>
<td>230</td>
<td>54</td>
</tr>
<tr>
<td>Affecteds</td>
<td>643 (510)</td>
<td>173 (141)</td>
</tr>
<tr>
<td>Patients per family</td>
<td>2.8 (2.3)</td>
<td>4.0 (2.6)</td>
</tr>
<tr>
<td>Large family subset†</td>
<td>3.6 (3.1)</td>
<td></td>
</tr>
<tr>
<td>Pairs</td>
<td>515 (292)</td>
<td>234 (114)</td>
</tr>
<tr>
<td>Parent-child</td>
<td>97 (6)</td>
<td>62 (4)</td>
</tr>
<tr>
<td>Avuncular</td>
<td>43 (4)</td>
<td>31 (10)</td>
</tr>
<tr>
<td>Cousin</td>
<td>12 (7)</td>
<td>22 (13)</td>
</tr>
<tr>
<td>Age at onset, mean±SD, y</td>
<td>75 ± 6</td>
<td>73 ± 7</td>
</tr>
</tbody>
</table>

†Numbers in parentheses are those actually sampled.

The sib pairs were comprised as follows: 199 sib pairs, 27 sib trios, and 2 sib quartets.

†There were a total of 43 families.

disease etiology; they can only be used to test existing “candidate” genes.

Genome search strategies have the disadvantage that they are considerably less sensitive than association studies and require large amounts of work in terms of sample collection, data generation, and data analysis. However, these studies have the potential to identify previously unsuspected loci. Given the uncertainty of the published disease associations, we initiated a genome search for other loci. During this process, Pericak-Vance and colleagues10 found their high-signature for this receptor, APOE4 allele.

Generation of Marker Data

The microsatellite polymorphisms were detected by polymerase chain reaction. The forward primers were labeled at the 5'-end with a 6-carboxyfluorescein known as 6-FAM, a tetrachlorinated analogue, or a hexachlorinated analogue (Perkin Elmer Systems, San Francisco, Calif). The total 5-mL reaction contained a 50-mg DNA genomic template, 3.5-mol/L end-labeled forward primer and unlabeled reverse primer, 0.2 mol/L each of dextrorosidose triphosphate, dextrogulosinose 5'-triphosphate, dextrocytidile 5'-triphosphate, dextroribothymide 5'-triphosphate, 1 unit of Taq DNA polymerase (Promega), and 1-µL 5× buffer (7.5-mmol/L magnesium chloride, 250-mmol/L potassium chloride, 50-mmol/L Tris hydrochloride [pH 8.3]). All reaction cocktails were distributed evenly to a 96-well Falcon assay plate using a Beckman-1000 workstation (Beckman Instruments, San Francisco, Calif). Polymerase chain reaction products were then diluted at least 8-fold using a Beckman-1000 workstation. A measurement of 0.8 µL of diluted polymerase chain reaction product was mixed with 2.5 µL of deionized formamide, 0.4 µL of internal lane standard TAMRA-550 (Perkin Elmer Systems), and 0.5 µL of blue dye, denatured at 97°C for 5 minutes, rapidly cooled on ice, and then electrophoresed on a 6% denaturing polyacrylamide gel and the alleles were detected on a 373-automated DNA sequencer (Perkin Elmer Systems, San Francisco, Calif) using GeneScan 2.1 (Perkin Elmer Systems). Two Centre Erute Polymorphism Humaine individuals (133101,133102) and 1 local DNA were loaded on every gel as controls. All alleles were initially assigned and genotyped semiautomatically using Genotyper 2.0 (Perkin Elmer Systems) without any information of phenotype. Laboratory personnel were masked to the phenotypic status of individual samples.

Statistical Analysis

Two-point and multipoint-affected sibling pair analysis was performed on the entire set of genotyped sibships (292 affected pairs) using MAPMAKER/SIBS.14 This program does not permit analysis of other affected pairings. In addition, the data set was divided into 2 subsamples, each of which was analyzed separately using MAPMAKER/SIBS. The first group consisted of sibling pairs who both possessed at least 1 APOE4 allele (162 affected pairs), and the second group consisted of sibling pairs in which neither member possessed an APOE4 allele (63 affected pairs). For example, a quartet of affected siblings whose APOE4 genotypes are APOE3/APOE3, APOE3/APOE4, and APOE3/APOE4 would contribute 1 pair to each group.

A multipoint exclusion map also was obtained for the entire sample using MAPMAKER/SIBS. For the purposes of this analysis, the disease-susceptibility model was parameterized in terms of λs, the relative risk to siblings of a case.15 A number of values of λs ranging from 1.2 to 2.0 were tested.

RESULTS

Two-point lod scores between markers and disease are shown in Table 2. Multipoint affected sibling pair analysis on the entire data set (292 sibling pairs), with lod scores, is shown in Figure 1. The maximum lod score obtained was 0.89 at D12S398, corresponding to a chromosome-wide P value of 0.21. If the multiple testing arising from the APOE4 positive and negative analyses is included, the P value increases to 48. These P values were simulated from our actual sample, using the observed marker allele frequencies and the marker map used in the analyses and thus should not be conservative. A lod score of zero, suggesting no excess of allele sharing between affected family members, was obtained in the region in which Pericak-Vance and colleagues10 found their highest lod scores.

We attempted to detect possible epistatic effects between APOE and a susceptibility locus on chromosome 12 by splitting the data set into 2 subsamples. The first portion contained sibling pairs who both possessed at least 1 APOE4 allele (162 pairs) and is denoted in Figure 1 by “APOE4 both positive.” The other subset contained sibling pairs with both members APOE4 negative (63 pairs), and is denoted in Figure 1 by “APOE4 both negative.” As shown in Figure 1, neither group had a significant lod score close to D12S1034. However, the subset of affected pairs who were both APOE negative had a multipoint lod of 1.91 at D12S86, corresponding to a chromosome-wide P value of approximately 0.09 (allowing for multiple testing). The α2-macroglobulin gene is between D12S88 and D12S397 at this peak, and Blacker
markers at three multipoint LOD scores were analyzed separately. The highest multipoint LOD scores are shown in Table 2. The LOD scores given by each locus agree with the evidence for linkage. Positive deviations from the chance give rise to positive LOD scores. Markers S373, S1027, S1057, S1042, and S1292 are those to which Pericak-Vance and colleagues\(^{10}\) reported genetic linkage. The LRP gene is located close to D12S398.

The results of the multipoint exclusion analysis performed on the entire data set are shown in Figure 2. For this analysis, the disease-susceptibility model was parameterized in terms of the relative risk to siblings of a case, \( \lambda_e \). Assuming the frequency of \( \text{APOE} \varepsilon 4 \) in the general population is 0.15, the relative risk to \( \varepsilon 4 \) heterozygotes is 4, and the relative risk to \( \varepsilon 4 \) homozygotes is 10\(^2\), then \( \lambda_e \) for the \( \text{APOE} \varepsilon 4 \) locus is approximately 1.4. As shown in Figure 2, when \( \lambda_e \) is 1.4, a region extending from D12S310 to 12 centimorgans distal of D12S1292 is excluded (LOD score < -2.0). (This region includes D12S1012, the locus to which Pericak-Vance and colleagues\(^{10}\) found their strongest evidence of linkage.)

To replicate the analysis of Pericak-Vance and colleagues\(^{10}\), we selected from our sample those families with at least 3 sampled affected individuals (see Table 1 for the structure of these “large pedigrees”) and analyzed these separately. The LOD scores given by each locus analyzed separately are shown in Table 2. The highest multipoint LOD scores were 0.47 at D12S98 and 0.44 at D12S895. This is consistent with the results obtained from the entire sample, although the LOD score is reduced, as would be expected from the reduction in sample size. In this analysis, multiply affected families are not greatly different from the others in terms of their evidence for linkage. However, our series of large families (at least 3 sampled individuals) contained half the number of sampled cousin and avuncular pairs than the data sets in the previous report. Thus, it remains possible that some differences in ascertainment between the 2 series could account for the discrepancies in the results.

**COMMENT**

Our findings should not be interpreted as indicating that there is no AD-risk gene close to D12S1012, since, as with the failures to repeat the observations of genetic associations, it remains possible that there is such a locus that is important in a few families including a proportion of those ascertained by Pericak-Vance and colleagues.\(^{10}\) However, it is unlikely that such a locus accounts for a large proportion of cases of AD, since we were not able to detect evidence of linkage in our entire data set. However, we were able to detect evidence of linkage to a marker near the \( \text{APOE} \varepsilon 4 \) locus using a dinucleotide repeat marker (D19S412). This marker gave a LOD score of 1.1 in our own and 2.1 when used in a multipoint with \( \text{APOE} \). These data, not surprisingly, resemble those reported by Blacker et al,\(^7\) since they consist of a highly over-

---

**Table 2.** Marker Information and 2-Point LOD Scores

<table>
<thead>
<tr>
<th>Locus</th>
<th>Map Position</th>
<th>Heterozygosity</th>
<th>No. of Families</th>
<th>No. of Sib Pairs</th>
<th>Identity by Descent</th>
<th>Lod Score (Data Set)</th>
<th>Lod Score (Large Families)</th>
<th>APOE ε4 Positive</th>
<th>APOE ε4 Negative</th>
</tr>
</thead>
<tbody>
<tr>
<td>S373</td>
<td>116</td>
<td>0.72</td>
<td>197</td>
<td>257</td>
<td>0.47</td>
<td>0</td>
<td>0.01</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>S393</td>
<td>131</td>
<td>0.66</td>
<td>189</td>
<td>251</td>
<td>0.54</td>
<td>0</td>
<td>0.03</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>S395</td>
<td>155</td>
<td>0.75</td>
<td>211</td>
<td>273</td>
<td>0.52</td>
<td>0</td>
<td>0.05</td>
<td>0.58</td>
<td>0.26</td>
</tr>
<tr>
<td>S397</td>
<td>163</td>
<td>0.84</td>
<td>204</td>
<td>266</td>
<td>0.51</td>
<td>0</td>
<td>0.01</td>
<td>0.07</td>
<td>0.06</td>
</tr>
<tr>
<td>S457</td>
<td>181</td>
<td>0.87</td>
<td>222</td>
<td>287</td>
<td>0.53</td>
<td>0</td>
<td>0.27</td>
<td>0.03</td>
<td>0.50</td>
</tr>
<tr>
<td>S486</td>
<td>216</td>
<td>0.94</td>
<td>222</td>
<td>287</td>
<td>0.50</td>
<td>0</td>
<td>0.05</td>
<td>0</td>
<td>0.01</td>
</tr>
<tr>
<td>S501</td>
<td>243</td>
<td>0.67</td>
<td>222</td>
<td>287</td>
<td>0.48</td>
<td>0</td>
<td>0.01</td>
<td>0</td>
<td>0.01</td>
</tr>
<tr>
<td>S508</td>
<td>266</td>
<td>0.55</td>
<td>222</td>
<td>287</td>
<td>0.48</td>
<td>0</td>
<td>0.01</td>
<td>0</td>
<td>0.01</td>
</tr>
<tr>
<td>S516</td>
<td>289</td>
<td>0.71</td>
<td>222</td>
<td>287</td>
<td>0.50</td>
<td>0</td>
<td>0.05</td>
<td>0</td>
<td>0.05</td>
</tr>
<tr>
<td>S530</td>
<td>302</td>
<td>0.69</td>
<td>222</td>
<td>287</td>
<td>0.48</td>
<td>0</td>
<td>0.01</td>
<td>0</td>
<td>0.01</td>
</tr>
<tr>
<td>S532</td>
<td>315</td>
<td>0.64</td>
<td>222</td>
<td>287</td>
<td>0.48</td>
<td>0</td>
<td>0.01</td>
<td>0</td>
<td>0.01</td>
</tr>
<tr>
<td>S539</td>
<td>338</td>
<td>0.73</td>
<td>222</td>
<td>287</td>
<td>0.50</td>
<td>0</td>
<td>0.05</td>
<td>0.58</td>
<td>0.26</td>
</tr>
<tr>
<td>S545</td>
<td>351</td>
<td>0.75</td>
<td>222</td>
<td>287</td>
<td>0.52</td>
<td>0</td>
<td>0.05</td>
<td>0</td>
<td>0.01</td>
</tr>
<tr>
<td>S558</td>
<td>374</td>
<td>0.64</td>
<td>222</td>
<td>287</td>
<td>0.48</td>
<td>0</td>
<td>0.01</td>
<td>0</td>
<td>0.01</td>
</tr>
<tr>
<td>S571</td>
<td>397</td>
<td>0.73</td>
<td>222</td>
<td>287</td>
<td>0.50</td>
<td>0</td>
<td>0.05</td>
<td>0</td>
<td>0.01</td>
</tr>
<tr>
<td>S580</td>
<td>410</td>
<td>0.67</td>
<td>222</td>
<td>287</td>
<td>0.48</td>
<td>0</td>
<td>0.01</td>
<td>0</td>
<td>0.01</td>
</tr>
<tr>
<td>S583</td>
<td>423</td>
<td>0.75</td>
<td>222</td>
<td>287</td>
<td>0.52</td>
<td>0</td>
<td>0.05</td>
<td>0</td>
<td>0.01</td>
</tr>
</tbody>
</table>

*Map positions obtained from the genome database. Marker heterozygosity estimated from our sample. LOD scores calculated as described in the text. Numbers of affected sib pairs are less than 292 because of data loss. Identity by descent proportion is calculated for the entire sample. Allele sharing of 0.5 would be expected by chance. Positive deviations from the chance give rise to positive LOD scores. Markers S373, S1027, S1057, S1042, and S1292 are those to which Pericak-Vance and colleagues\(^{10}\) reported genetic linkage. The LRP gene is located close to D12S398.*

---

The results of the multipoint exclusion analysis performed on the entire data set are shown in Figure 2. For this analysis, the disease-susceptibility model was parameterized in terms of the relative risk to siblings of a case, \( \lambda_e \). Assuming the frequency of \( \text{APOE} \varepsilon 4 \) in the general population is 0.15, the relative risk to \( \varepsilon 4 \) heterozygotes is 4, and the relative risk to \( \varepsilon 4 \) homozygotes is 10\(^2\), then \( \lambda_e \) for the \( \text{APOE} \varepsilon 4 \) locus is approximately 1.4. As shown in Figure 2, when \( \lambda_e \) is 1.4, a region extending from D12S310 to 12 centimorgans distal of D12S1292 is excluded (LOD score < -2.0). (This region includes D12S1012, the locus to which Pericak-Vance and colleagues\(^{10}\) found their strongest evidence of linkage.)

To replicate the analysis of Pericak-Vance and colleagues,\(^{10}\) we selected from our sample those families with at least 3 sampled affected individuals (see Table 1 for the structure of these “large pedigrees”) and analyzed these separately. The LOD scores given by each locus analyzed separately are shown in Table 2. The highest multipoint LOD scores were 0.47 at D12S98 and 0.44 at D12S895. This is consistent with the results obtained from the entire sample, although the LOD score is reduced, as would be expected from the reduction in sample size. In this analysis, multiply affected families are not greatly different from the others in terms of their evidence for linkage. However, our series of large families (at least 3 sampled individuals) contained half the number of sampled cousin and avuncular pairs than the data sets in the previous report. Thus, it remains possible that some differences in ascertainment between the 2 series could account for the discrepancies in the results.

**COMMENT**

Our findings should not be interpreted as indicating that there is no AD-risk gene close to D12S1012, since, as with the failures to repeat the observations of genetic associations, it remains possible that there is such a locus that is important in a few families including a proportion of those ascertained by Pericak-Vance and colleagues.\(^{10}\) However, it is unlikely that such a locus accounts for a large proportion of cases of AD, since we were not able to detect evidence of linkage in our entire data set. However, we were able to detect evidence of linkage to a marker near the \( \text{APOE} \varepsilon 4 \) locus using a dinucleotide repeat marker (D19S412). This marker gave a LOD score of 1.1 in our own and 2.1 when used in a multipoint with \( \text{APOE} \). These data, not surprisingly, resemble those reported by Blacker et al,\(^7\) since they consist of a largely over-
lacking series of samples. Furthermore, the sample we have used here was sufficiently powerful to exclude (lod < −2) a locus of similar effect size to that of APOE from the region in which Pericak-Vance and colleagues found their most significant results. It is therefore unlikely that the difference between our results and those of Pericak-Vance and colleagues is due to lack of power in our sample. We did obtain a moderate lod score (P = .09) in the subset of affected pairs where both members were APOE e4 negative, suggesting the possible involvement of a locus acting heterogeneously with APOE e4. This locus is exactly at the α2-macroglobulin locus, which Blacker and colleagues have recently suggested is associated with AD. This locus is more than 20 centimorgans from the region implicated by Pericak-Vance and colleagues.

The LRP gene is close to D12S398, but we are not able to confirm or refute the inference from association studies, which implicate this gene in the etiology of the disease. Our data suggest that LRP is not a gene of large effect. However, given the poor genetic resolution of these types of linkage studies, it remains possible that the LRP gene is within the “linked” region in the data set. If the α2-macroglobulin is a predisposing locus for AD, it will be important to examine the genetics of both LRP and its other ligands.

A serious problem in genome scans of complex disorders is the assessment of the true level of significance associated with a screen in which multiple tests are performed on a single data set. The problem is that such studies attempt to resolve complex issues with a single analysis: (1) determination of the inheritance characteristics of the locus (ie, mode of inheritance, age-dependent penetrance, “pheno-copy” or misdiagnosis rate, disease allele frequency, interaction with other [APOE] loci, etc) and (2) identification of the location of this putative gene. This is quite unlike maximum likelihood methods of analysis in simple Mendelian disorders in which the inheritance characteristics can be estimated to a high enough degree of certainty so as not to interfere with the localization. Modification of the analysis parameters or choosing a variety of linkage analyses and approaches amounts to multiple testing from a statistical perspective. Although multiple testing is legitimate part of trying to determine the inheritance characteristics of the phenotype, it means that lod scores derived from such analyses cannot be thought of as equivalent to the lod scores in simple disorders.

This work was supported by the British Medical Research Council, National Institutes of Health grant AG14616, the Alzheimer’s Association, and the Mayo Foundation. Alison Goate, PhD, is the recipient of National Institutes of Health career development award AG00634. The National Institutes of Mental Health provided the DNA samples used in this work.

References


©1998 American Medical Association. All rights reserved.